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costs in intraoperative changes of the surgical plan and reductions in unnecessary
surgery associated with the use of PV-MRI. Results from the previous study VALUE,
which showed that no patient with PV required additional imaging tests as part of
a Phase IV, confirm the results obtained in the present analysis (resulting in even
slightly lower cost than the total cost of diagnosis using PV-MRI).
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OBJECTIVES: Cervical cancer incidence in Serbia has been identified as one of the
highest in Europe, showing slow but steady increase during the last decade. De-
spite the National Programme for Prevention of Cervical Cancer that has recently
been established, an organised Pap screening is far from full implementation. This
study aims to assess the effectiveness and cost effectiveness of absolute adherence
to the proposed policy compared to the current practice. METHODS: A Markov
model simulating the natural history of cervical cancer was developed. Calibration
was performed using country specific data, sourcing incidence and mortality from
Serbian cancer registries. Accordingly, the screening algorithm incorporated in the
model was based on the local guidelines. We followed a hypothetical cohort of
100,000 15-year old girls until the end of their lifetime. Subsequently, the actual
cytological screening practice covering only 20% of the targeted population was
compared to a scenario of absolute adherence to the national screening pro-
gramme. A discount rate of 1.5% for health and 4% for cost outcomes was applied.
RESULTS: The natural history model showed that limited benefit is currently being
achieved from cytological screening. The hypothetical cohort analysis indicated
that absolute guidelines adherence would result in 422 deaths averted and an
incremental cost effectiveness ratio (ICER) of 3272 €/LYG. The ICER estimate did not
exceed the national annual GDP (3857 €/capita) - a commonly used informal
threshold. CONCLUSIONS: This research identified that full adherence to the
screening policy is very likely to be cost effective. In general, the low screening
coverage that has been observed appeared as the most serious obstacle to the
prevention of cervical cancer. The new methods in cervical cancer prevention,
however, such as HPV vaccination and HPV testing, require further pharmacoeco-
nomic assessment.
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OBJECTIVES: This study aimed to develop cost-effectiveness analysis of Soft Sili-
cone Wound-Contact Dressing (SS) versus Silver Sulphadiazine (SSD) in children
with partial-thickness scalds (PTS), under the perspective of Brazilian public
payers.METHODS: A literature search was conducted to gather efficacy data for SS
and SSD and identified one randomized controlled trial that compared median
time to 100% epithelialization (MTH) for SS and SSD. These data were used to
estimate clinical benefits in terms of “inpatient days avoided”. The model assumed
that SSD is the current practice in Brazilian public hospitals and patients are dis-
charged at the time their wound heals. Resource use was estimated through expert
panel, only direct medical costs were included in the analysis and unit costs were
obtained from Brazilian official price lists. RESULTS: The randomized trial ob-
served MTH of 10.5 and 27.6 days for SS and SSD, respectively (incremental effec-
tiveness of -17.1 days). Evidence from smaller observational studies have reported
intervals to SS change of up to 14 days, while SSD requires two changes per day.
Thus, the model estimated costs for the inpatient period assuming one dressing
change for SS and 28 changes for SSD. The cost per dressing change was estimated
as 33BRL for SS and 23BRL for SSD and the overall treatment costs were 1,261BRL
and 23BRL. SS-related incremental costs were -1228BRL indicating a cost-saving
profile. Benefits in terms of reduction in length of stay were not accounted in the
base case scenario. If average public hospital daily charges were included in the
cost estimation, savings would reach -2209BRL. CONCLUSIONS: SS dressing has
shown higher efficacy when compared to SSD, with fewer overall costs. The signif-
icant reduction in the median time to healing offset the higher unit cost by lower-
ing the number of required changes and the total length of stay.
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OBJECTIVES: A new ambulatory electrocardiogram (loop recorder) has been intro-
duced in Canada to detect arrhythmias, overcoming issues of previous recorders
with its capability of automatically detecting/sending electrocardiograph data and
simultaneously patient activation of device during symptoms. The loop recorder is
expected to have a higher diagnostic yield due to its recording capabilities and
longer test period (14days) however the cost is greater than the standard of care
(Holter). Cost-effectiveness was estimated for Holter versus the loop recorder for
diagnosing paroxysmal or persistent atrial fibrillation in primary physician care in
Ontario, Canada, from a health payer‘s perspective. METHODS: A probabilistic
decision analytic model was constructed to estimate cost, number of cases cor-
rectly detected, and number of strokes averted due to correct detection and treat-
ment over a 19 month period. Direct medical costs included diagnostic testing,
treatment of atrial fibrillation, prevention of stroke, and treatment of stroke. Costs
were expressed in 2011 Canadian dollars. One-way, multi-way and probabilistic
analyses of uncertainty were conducted. Model inputs were from various sources
including primary data, published literature and expert opinion.RESULTS:Average
cost was estimated at $490 for Holter, and $612 for loop recorder. Average cases of
atrial fibrillation correctly detected were 0.032 for Holter, and 0.058 for loop re-
corder. Average number of strokes averted were 0.010 for Holter and 0.018 for loop
recorder. The probabilistic mean incremental cost-effectiveness ratio of loop re-
corder versus Holter was $2430 per additional case correctly detected and $698 per
additional stroke averted. At a $20,000 willingness-to-pay threshold the probability
of the loop recorder being cost effective for cases detected and strokes averted were
95.5% and 60.4% respectively. Cases detected and strokes averted were 99.3% and
92% respectively for a willingness-to-pay of $50,000. CONCLUSIONS: Cost-effec-
tiveness analysis favours the new loop recorder compared to Holter.
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OBJECTIVES: The Corail™ Hip System, a hydroxyapatite coated cementless im-
plant, has demonstrated its high efficacy and safety for primary total hip arthro-
plasty (THA) for over 20 years. The objective of this work was to evaluate the
cost-effectiveness of the Corail™ Hip System in comparison with other cementless
hip designs (standard) in Spain. METHODS: An analytical decision-making model
was constructed as a Markov model for patients who were candidates to THA. The
study perspective was from the viewpoint of the Spanish National Health System
(NHS). Time horizons included in the model were 10 or 20 years and lifetime.
Healthcare costs associated with the compared interventions and their conse-
quences were expressed in euro 2011. Data came from a review of the literature and
was validated by local clinical experts. A discount rate of 3% was applied on costs
and efficacy data. RESULTS: The use of the Corail™ Hip System for THA compared
with the standard resulted in €4317 per revision avoided and €5812 per QALY
gained considering a time horizon of 10 years. The result was dominant in favour of
Corail™ when a time horizon of 20 years or lifetime was considered for all the
scores. Corail™ provided a gain of 0.075 QALY and saved €279 versus the standard
(lifetime). There were no significant differences between sexes. In the sensitivity
analysis was built the best scenario for Corail™ including the worse efficacy data
available for the standard and Corail™ resulted in a gain of 0.388 QALY and saved
€2226 (lifetime). The probabilistic sensitivity analysis showed that Corail™ was
cost-effective in 76% of cases (threshold of €30,000/QALY). CONCLUSIONS: Prelim-
inary results showed that the Corail™ Hip System is a cost-effective option in THA
compared with the rest of cementless hip trademarks available in Spain.
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OBJECTIVES: To compare the costs and effectiveness of the EX-PRESS glaucoma
filtration device (Alcon Inc, TX) to trabeculectomy, 5 years after surgery, in primary
open angle glaucoma (POAG). METHODS: Seventy-eight patients with POAG un-
controlled despite maximally-tolerated medical therapies were randomized to re-
ceive either the EX-PRESS or undergo a trabeculectomy, realized by a single sur-
geon. Outcomes captured over 5 years included intraocular pressure (IOP a
surrogate endpoint of glaucoma progression), use of IOP lowering medications and
additional eye surgeries. The economic perspective was the one of the Dutch Na-
tional Health System. Patients were considered a success if they had an IOP less
than or equal to the success thresholds of 15 or 18 mmHg, without IOP lowering
medications, and without having undergone further glaucoma surgery. Time to
failure was analyzed using a log rank test. Costs were discounted at a 4% rate.
EX-PRESS cost was not included. RESULTS: The 5-year failure rate was 41% for
EX-PRESS versus 69% for trabeculectomy (P0.005) using an 18 mmHg IOP target
and 46% versus 77% (P0.001) for 15 mmHg. EX-PRESS patients were less likely to
use medications, and among the medically treated patients, required fewer drugs.
EX-PRESS eyes required less needling (2 vs 5) and less cataract surgery (5 vs. 8).
Without discounting, drug savings with EX-PRESS equaled €333.86 and €107.79 for
eye surgery /laser, a total of €441.65. With a 4% discounting, the figures became
€310.45, €132.78 and €443.23, respectively. CONCLUSIONS: At 5 years after surgery,
EX-PRESS demonstrated that it better controls IOP than trabeculectomy, resulting
in savings in both IOP lowering drugs and eye surgeries. Economic benefits of the
better IOP control (less disease progression, i.e. a better vision) and saving accord-
ing to a lifelong time horizon will be estimated in future modelling exercises.
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OBJECTIVES: EX-PRESS glaucoma filtration device (Alcon Inc, TX) is an alternative
treatment to trabeculectomy, a surgery realized in advanced primary open angle
glaucoma (POAG). This analysis reports the incremental cost and benefits of
EX-PRESS. METHODS: Patients with POAG uncontrolled by maximally-tolerated
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